Sana Biotechnology (NASDAQ:SANA) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Sana Biotechnology (NASDAQ:SANA) in a research report sent to investors on Monday morning,Benzinga reports. They currently have a $8.00 target price on the stock.

SANA has been the subject of several other reports. JMP Securities cut Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 5th. Citigroup increased their price target on Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, August 9th.

Sana Biotechnology Price Performance

SANA stock opened at $2.89 on Monday. The stock has a market capitalization of $642.93 million, a P/E ratio of -2.06 and a beta of 1.44. The business has a 50-day moving average of $4.14 and a 200-day moving average of $5.73. Sana Biotechnology has a fifty-two week low of $2.76 and a fifty-two week high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.01. Equities analysts expect that Sana Biotechnology will post -1.13 EPS for the current year.

Insider Activity at Sana Biotechnology

In related news, Director Richard Mulligan sold 150,000 shares of the stock in a transaction that occurred on Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total transaction of $612,000.00. Following the completion of the transaction, the director now directly owns 2,848,121 shares of the company’s stock, valued at approximately $11,620,333.68. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 31.10% of the company’s stock.

Institutional Trading of Sana Biotechnology

Several institutional investors and hedge funds have recently bought and sold shares of the business. ProShare Advisors LLC increased its stake in shares of Sana Biotechnology by 14.8% during the first quarter. ProShare Advisors LLC now owns 32,690 shares of the company’s stock worth $327,000 after purchasing an additional 4,210 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Sana Biotechnology by 20.6% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,858 shares of the company’s stock worth $163,000 after purchasing an additional 5,090 shares during the period. Arizona State Retirement System increased its stake in shares of Sana Biotechnology by 36.7% during the second quarter. Arizona State Retirement System now owns 37,028 shares of the company’s stock worth $202,000 after purchasing an additional 9,940 shares during the period. Blue Trust Inc. increased its stake in shares of Sana Biotechnology by 1,246.6% during the third quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock worth $55,000 after purchasing an additional 12,154 shares during the period. Finally, Algert Global LLC bought a new position in shares of Sana Biotechnology during the second quarter worth approximately $73,000. Institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.